Study of Efficacy and Safety of CTL019 in Pediatric ALL Patients
NCT02435849
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
80
Enrollment
INDUSTRY
Sponsor class
Conditions
B-cell Acute Lymphoblastic Leukemia
Interventions
BIOLOGICAL:
CTL019
Sponsor
Novartis Pharmaceuticals